VERAXA Biotech AG (NASDAQ: VRXA) has announced the appointment of Carl von Halem as interim chief financial officer, effective immediately. Von Halem succeeds Torsten Bürgermeister and will lead the company's finance function during the transition period. The company stated that it is in the final stages of discussions with a permanent CFO candidate expected to support its next phase of expansion and operational growth, with an update to be provided in due course.
Von Halem currently serves as chief financial officer of Xlife Sciences and played a key role in VERAXA’s public listing. The company cited his experience in corporate finance, life sciences and technology-driven businesses, as well as his familiarity with VERAXA’s operations and strategic development, as key qualifications for leading the finance function during the transition. His deep understanding of the company's financial landscape and strategic goals positions him to effectively guide VERAXA through this interim period.
This leadership change comes at a critical time for VERAXA, which is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
The appointment of an interim CFO and the search for a permanent candidate signal VERAXA’s commitment to strengthening its financial leadership as it scales operations. For investors and industry observers, the stability of the finance function is critical as the company progresses its pipeline toward clinical milestones. The interim CFO's familiarity with the company's operations and strategic development is expected to ensure continuity in financial planning and reporting.
For more details on the announcement, visit the full press release at https://nnw.fm/BjjY6. The latest news and updates relating to VRXA are available in the company’s newsroom at http://nnw.fm/VRXA.
